Lifecore Biomedical (LFCR) director awarded 25,907 restricted stock units

Rhea-AI Filing Summary

Lifecore Biomedical director Joshua Schechter received an equity grant as part of his compensation. On the reported date, he was awarded 25,907 restricted stock units that convert into common stock on a 1-for-1 basis at no cash cost to him.

The grant vests on the earlier of June 4, 2027 or the date of the company’s annual meeting of stockholders first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026. After this award, Schechter directly holds 133,080 shares of Lifecore common stock.

Insights

Equity compensation analyst

Director receives routine restricted stock unit grant with time-based vesting.

Director Joshua Schechter was granted 25,907 restricted stock units that convert into Lifecore common shares on a 1-for-1 basis at a price of $0.00 per share. This is a non-cash compensation award rather than an open-market purchase.

The units vest on the earlier of June 4, 2027 or the first annual meeting in calendar year 2027, if that meeting is at least 50 weeks after June 4, 2026. Following the grant, Schechter holds 133,080 shares directly, indicating this is a modest, routine addition to an existing position rather than a large directional trade.

Insider Trade Summary

Net Buyer: 25,907 shares

Net Buy 1 txn

Insider Schechter Joshua

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,907	$0.00	$0.00

Holdings After Transaction: Common Stock — 133,080 shares (Direct)

Footnotes (2)

1. F1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
2. F2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Key Figures

RSU grant size: 25,907 shares Grant price: $0.00 per share Post-grant holdings: 133,080 shares +2 more

5 metrics

RSU grant size 25,907 shares Restricted stock units granted to director Joshua Schechter

Grant price $0.00 per share Compensation award, not open-market purchase

Post-grant holdings 133,080 shares Total common shares directly held after transaction

RSU conversion ratio 1-for-1 into common stock Restricted stock units convert into Lifecore common shares

Latest vesting date June 4, 2027 Time-based vesting trigger for RSUs, subject to meeting timing

Key Terms

restricted stock units, annual meeting of stockholders, 1 for 1 basis, Grant, award, or other acquisition

4 terms

restricted stock units financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual meeting of stockholders financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders"

1 for 1 basis financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/05/2026 - 04:46 PM Accepted by SEC EDGAR 06/05/2026 - 04:46 PM Learn about SEC filing dates

FAQ

What did Lifecore Biomedical (LFCR) director Joshua Schechter receive in this Form 4 filing?

Joshua Schechter received an equity award of 25,907 restricted stock units that convert into common stock on a 1-for-1 basis. The grant is a non-cash compensation award, not an open-market stock purchase, and increases his direct holdings in Lifecore Biomedical.

At what price were the Lifecore Biomedical (LFCR) shares granted to Joshua Schechter?

The 25,907 restricted stock units were granted at a price of $0.00 per share, reflecting a compensation award rather than a purchase. These units convert into common stock of Lifecore Biomedical on a 1-for-1 basis once they vest under the stated schedule.

When do Joshua Schechter’s restricted stock units in Lifecore Biomedical (LFCR) vest?

The restricted stock units vest on the earlier of June 4, 2027 or the date of Lifecore’s annual stockholder meeting first held in calendar year 2027. That meeting must occur at least 50 weeks after June 4, 2026 for the alternative vesting date to apply.

How many Lifecore Biomedical (LFCR) shares does Joshua Schechter hold after this transaction?

Following this equity grant, Joshua Schechter directly holds 133,080 shares of Lifecore Biomedical common stock. This figure includes the effect of the new restricted stock unit award reported in the filing and reflects his post-transaction direct ownership position.

Is the Lifecore Biomedical (LFCR) Form 4 for Joshua Schechter a buy or sell transaction?

The Form 4 reports an acquisition through a grant of restricted stock units, not a market buy or sell. The transaction code is “A” for a grant or award, indicating routine equity compensation rather than an insider trading decision in the open market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schechter Joshua

(Last) (First) (Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA MINNESOTA 55318

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		25,907	A	(1)(2)	133,080	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Remarks:

	/s/ Courtney Schuler, Attorney-In-Fact for Joshua Schechter	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)